The Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

Frontiers in Bioscience

Volumn 10, Issue SUPPL. 3, 2005, Pages 2986-3001

  Meier, Friedegund ^a   Schittek, Birgit ^a   Busch, Silke ^a   Garbe, Claus ^a   Smalley, Keiran ^b   Satyamoorthy, Kapaettu ^b   Li, Gang ^b   Herlyn, Meenhard ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b WISTAR INSTITUTE   (United States)

Author keywords

AKT; Cancer; ERK; Malignant; MEK; Melanoma; Meloncyte; Pathway; PI3K; Raf; Ras; Review; Signaling; Skin; Tumor

Indexed keywords

CELL ADHESION MOLECULE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; UVOMORULIN; VITRONECTIN RECEPTOR;

APOPTOSIS; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; INCIDENCE; MELANOMA; PIGMENT CELL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 21344456180     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1755     Document Type: Review

References (97)

1. Hall HI, D.R.Miller, J.D.Rogers &B.Bewerse: Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 40, 35-42 (1999)
2. Perlis C &M.Herlyn: Recent advances in melanoma biology. The Oncologist 9, 182-187 (2004)
3. Balch CM, A.C.Buzaid, S.J.Soong, M.B.Atkins, N.Cascinelli, D.G.Coit, I.D.Fleming, J.E.Gershenwald, A.J.Houghton, J.M.Kirkwood, K.M.McMasters, M.F.Mihm, D.L.Morton, D.S.Reintgen, M.I.Ross, A.Sober, J.A.Thompson &J.F.Thompson: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19, 3635-3648 (2001)
4. Hilger RA, M.E.Scheulen &D.Strumberg: The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25, 511-518 (2002)
5. Cobb MH: MAP kinase pathways. Prog Biophys Mol Biol 71, 479-500 (1999)
6. Smalley KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104, 527-532 (2003)
7. van Elsas A, S.Zerp, S.van der Flier, M.Kruse-Wolters, A.Vacca, D.J.Ruiter &P.Schrier: Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single- stranded conformation polymorphism analysis. Recent Results Cancer Res 139, 57-67 (1995)
8. Carr J, R.M.MacKie: Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 131, 72-77 (1994)
9. Davies H, G.R.Bignell, C.Cox, P.Stephens, S.Edkins, S.Clegg, J.Teague, H.Woffendin, M.J.Garnett, W.Bottomley, N.Davis, E.Dicks, R.Ewing, Y.Floyd, K.Gray, S.Hall, R.Hawes, J.Hughes, V.Kosmidou, A.Menzies, C.Mould, A.Parker, C.Stevens, S.Watt, S.Hooper, R.Wilson, H.Jayatilake, B.A.Gusterson, C.Cooper, J.Shipley, D.Hargrave, K.Pritchard-Jones, N.Maitland, G.Chenevix-Trench, G.J.Riggins, D.D.Bigner, G.Palmieri, A.Cossu, A.Flanagan, A.Nicholson, J.W.Ho, S.Y.Leung, S.T.Yuen, B.L.Weber, H.F.Seigler, T.L.Darrow, H.Paterson, R.Marais, C.J.Marshall, R.Wooster, M.R.Stratton &P.A.Futreal: Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002)
10. Wan PT, M.J.Garnett, S.M.Roe, S.Lee, D.Niculescu-Duvaz, V.M.Good, C.M.Jones, C.J.Marshall, C.J.Springer, D.Barford &R.Marais: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004)
11. Maldonado JL, J.Fridlyand, H.Patel, A.N.Jain, K.Busam, T.Kageshita, T.Ono, D.G.Albertson, D.Pinkel &B.C.Bastian: Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95, 1878-1890 (2003)
12. Edwards RH, M.R.Ward, H.Wu, C.A.Medina, M.S.Brose, P.Volpe, S.Nussen-Lee, H.M.Haupt, A.M.Martin, M.Herlyn, S.R.Lessin &B.L.Weber: Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 41, 270-272 (2004)
13. Pollock PM, U.L.Harper, K.S.Hansen, L.M.Yudt, M.Stark, C.M.Robbins, T.Y.Moses, G.Hostetter, U.Wagner, J.Kakareka, G.Salem, T.Pohida, P.Heenan, P.Duray, O.Kallioniemi, N.K.Hayward, J.M.Trent &P.S.Meltzer: High frequency of BRAF mutations in nevi. Nat Genet 33, 19-20 (2003)
14. Cohen C, A.Zavala-Pompa, J.H.Sequeira, M.Shoji, D.G.Sexton, G.Cotsonis, F.Cerimele, B.Govindarajan, N.Macaron &J.L.Arbiser: Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8, 3728-3733 (2002)
15. Schuierer MM, F.Bataille, S.Hagan, W.Kolch &A.K.Bosserhoff: Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64, 5186-5192 (2004)
16. Maldonado JL, L.Timmerman, J.Fridlyand &B.C.Bastian: Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am J Pathol 164, 1783-1787 (2004)
17. Arbiser JL: Activation of B-raf in non-malignant nevi predicts a novel tumor suppressor gene in melanoma (MAP kinase phosphatase). J Invest Dermatol 121, xiv (2003)
18. Tanami H, I.Imoto, A.Hirasawa, Y.Yuki, I.Sonoda, J.Inoue, K.Yasui, A.Misawa-Furihata, Y.Kawakami &J.Inazawa: Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 23, 8796-8804 (2004)
19. Rodeck U, D.Becker &M.Herlyn: Basic fibroblast growth factor in human melanoma. Cancer Cells 3, 308-311 (1991)
20. Kinkl N, J.Sahel &D.Hicks: Alternate FGF2-ERK1/2 signaling pathways in retinal photoreceptor and glial cells in vitro. J Biol Chem 276, 43871-43878 (2001)
21. Li G, H.Schaider, K.Satyamoorthy, Y.Hanakawa, K.Hashimoto &M.Herlyn: Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 20, 8125-8135 (2001)
22. Satyamoorthy K, G.Li, M.R.Gerrero, M.S.Brose, P.Volpe, B.L.Weber, P.Van Belle, D.E.Elder &M.Herlyn: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63, 756-759 (2003)
23. Herlyn M, I.M.Shih: Interactions of melanocytes and melanoma cells with the microenvironment. Pigment Cell Res 7, 81-88 (1994)
24. Herlyn M, J.Thurin, G.Balaban, J.L.Bennicelli, D.Herlyn, D.E.Elder, E.Bondi, D.Guerry, P.Nowell &W.H.Clark: Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 45, 5670-5676 (1985)
25. Kanter-Lewensohn L, A.Dricu, M.Wang, J.Wejde, R.Kiessling &O.Larsson: Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target. Melanoma Res 8, 389-397 (1998)
26. Satyamoorthy K, G.Li, B.Vaidya, D.Patel &M.Herlyn: Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 61, 7318-7324 (2001)
27. Hsu MY, D.T.Shih, F.E.Meier, P.Van Belle, J.Y.Hsu, D.E.Elder, C.A.Buck &M.Herlyn: Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma [see comments]. Am J Pathol 153, 1435-1442 (1998)
28. Stupack DG, D.A.Cheresh: Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 115, 3729-3738 (2002)
29. Li G, J.Kalabis, X.Xu, F.Meier, M.Oka, T.Bogenrieder &M.Herlyn: Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene 22, 6891-6899 (2003)
30. Li G, K.Satyamoorthy &M.Herlyn: N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 61, 3819-3825 (2001)
31. Bao W, S.Stromblad: Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. J Cell Biol 167, 745-756 (2004)
32. Welsh CF, K.Roovers, J.Villanueva, Y.Liu, M.A.Schwartz &R.K.Assoian: Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol 3, 950-957 (2001)
33. Pages G, P.Lenormand, G.L'Allemain, J.C.Chambard, S.Meloche &J.Pouyssegur: Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A 90, 8319-8323 (1993)
34. Smalley K, T.Eisen: The involvement of p38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone (alpha-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. FEBS Lett 476, 198-202 (2000)
35. Smalley KS, T.G.Eisen: Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest. Melanoma Res 12, 187-192 (2002)
36. Kortylewski M, P.C.Heinrich, M.E.Kauffmann, M.Bohm, A.MacKiewicz &I.Behrmann: Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem J 357, 297-303 (2001)
37. Karasarides M, A.Chiloeches, R.Hayward, D.Niculescu-Duvaz, I.Scanlon, F.Friedlos, L.Ogilvie, D.Hedley, J.Martin, C.J.Marshall, C.J.Springer &R.Marais: B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292-6298 (2004)
38. Sumimoto H, M.Miyagishi, H.Miyoshi, S.Yamagata, A.Shimizu, K.Taira &Y.Kawakami: Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23, 6031-6039 (2004)
39. Hingorani SR, M.A.Jacobetz, G.P.Robertson, M.Herlyn &D.A.Tuveson: Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63, 5198-5202 (2003)
40. Huntington JT, J.M.Shields, C.J.Der, C.A.Wyatt, U.Benbow, C.L.J.Slingluff &C.E.Brinckerhoff: Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem 279, 33168-33176 (2004)
41. Goodall J, C. Wellbrock, T.J.Dexter, K.Roberts, R.Marais &C.R.Goding: The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol 24, 2923-2931 (2004)
42. King R, K.N.Weilbaecher, G.McGill, E.Cooley, M.Mihm &D.E.Fisher: Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis. Am J Pathol 155, 731-738 (1999)
43. McGill GG, M.Horstmann, H.R.Widlund, J.Du, G.Motyckova, E.K.Nishimura, Y.L.Lin, S.Ramaswamy, W.Avery, H.F.Ding, S.A.Jordan, I.J.Jackson, S.J.Korsmeyer, T.R.Golub &D.E.Fisher: Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell109, 707-718 (2002)
44. Eisenmann KM, M.W.VanBrocklin, N.A.Staffend, S.M.Kitchen &H.M.Koo: Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 63, 8330-8337 (2003)
45. Zhang XD, J.M.Borrow, X.Y.Zhang, T.Nguyen &P.Hersey: Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22, 2869-2881 (2003)
46. Woods D, H.Cherwinski, E.Venetsanakos, A.Bhat, S.Gysin, M.Humbert, P.F.Bray, V.L.Saylor &M.McMahon: Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol 7 21, 3192-3205 (2001)
47. Petitclerc E, S.Stromblad, T.L.von Schalscha, F.Mitjans, J.Piulats, A.M.Montgomery, D.A.Cheresh &P.C.Brooks: Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 59, 2724-2730 (1999)
48. Hsu MY, M.J.Wheelock, K.R.Johnson &M.Herlyn: Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1, 188-194 (1996)
49. Hsu MY, F.Meier &M.Herlyn: Melanoma development and progression: a conspiracy between tumor and host. Differentiation 70, 522-536 (2002)
50. Van Belle PA, R.Elenitsas, K.Satyamoorthy, J.T.Wolfe, D.Guerry, L.Schuchter, T.J.Van Belle, S.Albelda, P.Tahin, M.Herlyn &D.E.Elder: Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol 30, 562-567 (1999)
51. Hofmann UB, J.R.Westphal, A.A. Van Kraats, D.J.Ruiter &G.N.Van Muijen: Expression of integrin alpha(v)beta(3) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo. Int J Cancer 87, 12-19 (2000)
52. Benbow U, G.B.Tower, C.A.Wyatt, G.Buttice &C.E.Brinckerhoff: High levels of MMP-1 expression in the absence of the 2G single nucleotide polymorphism is mediated by p38 and ERK1/2 mitogen-activated protein kinases in VMM5 melanoma cells. J Cell Biochem 86, 307-319 (2002)
53. Ge X, Y.M.Fu &G.G.Meadows: U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. Cancer Lett 179, 133-140 (2002)
54. Tower GB, C.C.Coon, U.Benbow, M.P.Vincenti &C.E.Brinckerhoff: Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. Biochim Biophys Acta 1586, 265-274 (2002)
55. Bedogni B, M.S.O'Neill, S.M.Welford, D.M.Bouley, A.J.Giaccia, N.C.Denko &M.B.Powell: Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 64, 2552-2560 (2004)
56. Denkert C, A.Siegert, A.Leclere, A.Turzynski &S.Hauptmann: An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells. Clin Exp Metastasis 19, 79-85 (2002)
57. Fresno VJ, E.Casado, J.de Castro, P.Cejas, C.Belda-Iniesta &M.Gonzalez-Baron: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30, 193-204 (2004)
58. Nicholson KM, N.G.Anderson: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14, 381-395 (2002)
59. Dhawan P, A.B.Singh, D.L.Ellis &A.Richmond: Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 62, 7335-7342 (2002)
60. Dai DL, M.Martinka &G.Li: Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23, 1473-1482 (2005)
61. Simpson L, R.Parsons: PTEN: life as a tumor suppressor. Exp Cell Res 264, 29-41 (2001)
62. Bastian BC, P.E.LeBoit, H.Hamm, E.B.Brocker &D.Pinkel: Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58, 2170-2175 (1998)
63. Stahl JM, M.Cheung, A.Sharma, N.R.Trivedi, S.Shanmugam &G.P.Robertson: Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 63, 2881-2890 (2003)
64. Stahl JM, A.Sharma, M.Cheung, M.Zimmerman, J.Q.Cheng, M.W.Bosenberg, M.Kester, L.Sandirasegarane &G.P.Robertson: Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64, 7002-7010 (2004)
65. Rodriguez-Viciana P, P.H.Warne, A.Khwaja, B.M.Marte, D.Pappin, P.Das, M.D.Waterfield, A.Ridley &J.Downward: Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89, 457-467 (1997)
66. Kauffmann-Zeh A, P.Rodriguez-Viciana, E.Ulrich, C.Gilbert, P.Coffer, J.Downward &G.Evan: Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385, 544-548 (1997)
67. Graells J, A.Vinyals, A.Figueras, A.Llorens, A.Moreno, J.Marcoval, F.J.Gonzalez &A.Fabra: Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 123, 1151-1161 (2004)
68. Hsu MY, F.E.Meier, M.Nesbit, J.Y.Hsu, P.Van Belle, D.E.Elder &M.Herlyn: E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 156, 1515-1525 (2000)
69. Satyamoorthy K, Muyrers J, Meier F, Patel D, & erlyn M: Mel-CAM-specific genetic suppresor elements inhibit melanoma growth and invasion through loss of gap junctional communication. 20, 4676-4684 (2001)
70. Sturm RA, K.Satyamoorthy, F.Meier, B.B.Gardiner, D.J.Smit, B.Vaidya &M.Herlyn: Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Res 62, 226-232 (2002)
71. Testa JR, A.Bellacosa: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 98, 10983-10985 (2001)
72. Kandasamy K, R.K.Srivastava: Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 62, 4929-4937 (2002)
73. Wang Q, X.Wang, A.Hernandez, M.R.Hellmich, Z.Gatalica &B.M.Evers: Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 277, 36602-36610 (2002)
74. Yuan XJ, Y.E.Whang: PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 21, 319-327 (2002)
75. Jiang K, J.Sun, J.Cheng, J.Y.Djeu, S.Wei &S.Sebti: Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol 24, 5565-5576 (2004)
76. Jetzt A, J.A.Howe, M.T.Horn, E.Maxwell, Z.Yin, D.Johnson &C.C.Kumar: Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice. Cancer Res 63, 6697-6706 (2003)
77. Krasilnikov M, V.N.Ivanov, J.Dong &Z.Ronai: ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22, 4092-4101 (2003)
78. Murakami T, A.R.Cardones, S.E.Finkelstein, N.P.Restifo, B.A.Klaunberg, F.O.Nestle, S.S.Castillo, P.A.Dennis &S.T.Hwang: Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med 198, 1337-1347 (2003)
79. Stewart AL, A.M.Mhashilkar, X.H.Yang, S.Ekmekcioglu, Y.Saito, K.Sieger, R.Schrock, E.Onishi, X.Swanson, J.B.Mumm, L.Zumstein, G.J.Watson, D.Snary, J.A.Roth, E.A.Grimm, R.Ramesh &S.Chada: PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med 8, 451-461 (2002)
80. Larribere L, M.Khaled, S.Tartare-Deckert, R.Busca, F.Luciano, K.Bille, G.Valony, A.Eychene, P.Auberger, J.P.Ortonne, R.Ballotti &C.Bertolotto: PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 11, 1084-1091 (2004)
81. Mills L, C.Tellez, L.Baker, J.Green, J.Gudas, X.Feng, & M.Bar-Eli: Fully human antibodies to MUC18 inhibits tumor growth and metastasis of human melanoma. Cancer Res 62, 5106-5114 (2002)
82. Diehl JA, M.Cheng, M.F.Roussel &C.J.Sherr: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12, 3499-3511 (1998)
83. Zhou BP, Y.Liao, W.Xia, Y.Zou, B.Spohn &M.C.Hung: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3, 973-982 (2001)
84. Liang J, J.Zubovitz, T.Petrocelli, R.Kotchetkov, M.K.Connor, K.Han, J.H.Lee, S.Ciarallo, C.Catzavelos, R.Beniston, E.Franssen &J.M.Slingerland: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8, 1153-1160 (2002)
85. Sherr CJ, J.D.Weber: The ARF/p53 pathway. Curr Opin Genet Dev 10, 94-99 (2000)
86. Tee AR, D.C.Fingar, B.D.Manning, D.J.Kwiatkowski, L.C.Cantley &J.Blenis: Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99, 13571-13576 (2002)
87. Potter CJ, L.G.Pedraza &T.Xu: Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4, 658-665 (2002)
88. Manning BD, A.R.Tee, M.N.Logsdon, J.Blenis &L.C.Cantley: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10, 151-162 (2002)
89. Inoki K, Y.Li, T.Zhu, J.Wu &K.L.Guan: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4, 648-657 (2002)
90. Dan HC, M.Sun, L.Yang, R.I.Feldman, X.M.Sui, C.C.Ou, M.Nellist, R.S.Yeung, D.J.Halley, S.V.Nicosia, W.J.Pledger &J.Q.Cheng: Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277, 35364-35370 (2002)
91. Holzmann B, E.B.Brocker, J.M.Lehmann, D.J.Ruiter, C.Sorg, G.Riethmuller &J.P.Johnson: Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 39, 466-471 (1987)
92. Xie S, M.Luca, S.Huang, M.Gutman, R.Reich, J.P.Johnson &M.Bar-Eli: Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 57, 2295-2303 (1997)
93. Shih IM, D.Speicher, M.Y.Hsu, E.Levine &M.Herlyn: Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res 57, 3835-3840 (1997)
94. Ahmad T, R.Marais, L.Pyle, M.James, B.Schwartz, M.Gore, & T.Eisen: BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22, 7506 (2004)
95. Flaherty K T, M.Brose, L.Schuchter, D.Tuveson, R.Lee, B.Schwartz, C.Lathia, B.Weber, & P.O'Dwyer: Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22, 7507 (2004)
96. Druker BJ, C.L.Sawyers, H.Kantarjian, D.J.Resta, S.F.Reese, J.M.Ford, R.Capdeville &M.Talpaz: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344, 1038-1042 (2001)
97. Demetri GD, M.von Mehren, C.D.Blanke, A.D.Van den Abbeele, B.Eisenberg, P.J.Roberts, M.C.Heinrich, D.A.Tuveson, S.Singer, M.Janicek, J.A.Fletcher, S.G.Silverman, S.L.Silberman, R.Capdeville, B.Kiese, B.Peng, S.Dimitrijevic, B.J.Druker, C.Corless, C.D.Fletcher &H.Joensuu: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347, 472-480 (2002)